Furthermore, interestingly, several previous studies demonstrated Andro’s biological properties in RAS-transformed cancer cells [85,86], suggesting Andro’s promising potential against PDAC, where more than 90% have mutations of KRAS [73,74]. Here, KRAS is linked to cancer.